New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 9, 2014
07:07 EDTLXRXLexicon and JDRF collaborate for Phase 2 trial of LX4211 in Type 1 diabetes
Lexicon announced that JDRF, the world's largest non-profit supporter of type 1 diabetes research, will provide funding to support a Phase 2, randomized, double-masked, placebo-controlled clinical trial to evaluate the efficacy and safety of LX4211 in a younger population with T1D. The primary objective of this study is to demonstrate the superiority of LX4211 versus placebo as adjunct to insulin treatment on HbA1c reduction at 12 weeks as well as several secondary endpoints, including reduced variability in blood glucose levels and lower insulin needs.
News For LXRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 4, 2015
09:08 EDTLXRXOn The Fly: Pre-market Movers
Subscribe for More Information
07:02 EDTLXRXLexicon reports Q4 EPS (0c), consensus (3c)
Subscribe for More Information
March 3, 2015
15:20 EDTLXRXNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include PetSmart (PETM), consensus $1.38... Trina Solar (TSL), consensus 13c... Lexicon Pharmaceuticals (LXRX), consensus (3c)... Abercrombie & Fitch (ANF), consensus $1.15... American Eagle Outfitters (AEO), consensus 34c... E. W. Scripps (SSP), consensus 40c.
March 2, 2015
07:20 EDTLXRXCowen to hold a conference
Subscribe for More Information
February 23, 2015
16:34 EDTLXRXLexicon Chief Scientific Officer resigns
Lexicon Pharmaceuticals announced the resignation of Brian Zambrowicz, Ph.D., executive vice president and Chief Scientific Officer, to pursue another opportunity. Dr. Zambrowicz will be assisting in shifting his responsibilities to other members of the company in order to ensure a seamless transition. In connection with the change, Lexicon will merge its discovery and clinical functions and conduct an immediate search for a head of research and development. Dr. Zambrowicz has agreed to be available to provide consulting services as the company completes this transition.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use